Related Experiment Videos

Modulatory effects of inflammation and therapy on GDF-5 expression in rheumatoid arthritis synovium

C P Bramlage1, C Kaps, U Ungethüm

  • 1Department of Medicine, Nephrology and Rheumatology, Georg-August-University Gottingen, Gottingen. c.bramlage@med.uni-goettingen.de

Scandinavian Journal of Rheumatology
|October 3, 2008
PubMed
Abstract

Insights

Growth differentiation factor-5 (GDF-5) is found in synovial fibroblasts and may reduce macrophage infiltration in joints. Glucocorticoids suppress GDF-5, potentially hindering joint repair mechanisms.

Area of Science:

  • Rheumatology
  • Cell Biology
  • Molecular Biology

Background:

  • Growth differentiation factor-5 (GDF-5), a TGF-beta family member, is crucial for joint development and has cartilage regeneration potential.
  • Synovial tissue cytokines influence chronic joint disease progression.

Purpose of the Study:

  • To investigate the expression and effects of GDF-5 within synovial tissue.
  • To understand GDF-5's role in osteoarthritis (OA) and rheumatoid arthritis (RA).

Main Methods:

  • Microarray, RT-PCR, immunohistochemistry, and in situ hybridization were used to analyze GDF-5 expression in synovial tissues.
  • Fibroblast cultures from OA and RA patients were stimulated with inflammatory cytokines and therapeutic agents (IL-1beta, TNF-alpha, MTX, prednisolone).
  • Macrophage chemotaxis assays assessed the influence of GDF-5 on cell migration.

Main Results:

  • GDF-5 was primarily expressed in synovial fibroblasts.
  • GDF-5 expression was significantly decreased in patients treated with glucocorticoids and/or DMARDs.
  • Prednisolone and TNF-alpha reduced GDF-5 expression in OA and RA fibroblasts, while MTX and IL-1beta had minimal effects.
  • GDF-5 significantly inhibited macrophage migration.

Conclusions:

  • GDF-5 is present in synovial fibroblasts and may inhibit macrophage infiltration, a key process in joint inflammation.
  • Therapeutic modulation of GDF-5 by anti-inflammatory drugs, particularly glucocorticoids, suggests a potential conflict between inflammation suppression and cartilage repair facilitation.

Related Concept Videos

T Cell Types and Functions01:24

T Cell Types and Functions

When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Inflammatory Response01:28

Inflammatory Response

An inflammatory response is a localized, nonspecific immune reaction that occurs when a tissue is injured. It is characterized by redness, swelling, heat, and pain, which are commonly called the cardinal signs and symptoms of inflammation. Inflammation can sometimes result in a loss of function.
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
Acute Inflammation III: Local and Systemic Effects01:25

Acute Inflammation III: Local and Systemic Effects

Acute inflammation produces a coordinated set of local and systemic changes that limit injury, eliminate pathogens, and initiate repair. These responses arise within minutes of infection, trauma, or chemical insult and are driven by vascular alterations and leukocyte-derived mediators. When the stimulus resolves, the reaction typically abates within days.Local EffectsAt the site of injury, arteriolar vasodilation increases blood flow, resulting in redness and warmth. Simultaneously, increased...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Inflammation: Introduction01:28

Inflammation: Introduction

Inflammation is a fundamental, protective biological response of vascularized tissues to cellular injury, infection, or harmful stimuli. Its primary function is to eliminate the initial cause of injury, clear necrotic cells and damaged tissue, and initiate the necessary repair processes.Cardinal SignsAcute inflammation presents with classic signs. Redness results from vasodilation and increased blood flow. Heat is due to increased metabolism and circulation. Swelling results from the...